ArticleEJNMMI research2026
Prospective comparison of [
Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPrimary Sjögren's syndrome (pSS) is characterized by progressive fibro-inflammatory glandular injury. While conventional salivary gland scintigraphy (SGS) provides macroscopic functional assessment, it cannot visualize underlying active fibrotic remodeling. This prospective study aimed to evaluate the diagnostic performance of dual-time-point (10 and 40 min post-injection) [
resultsAmong 21 participants (15 with confirmed pSS, 6 non-SS controls with other autoimmune diseases), early-phase (10-minute) PET/CT achieved optimal diagnostic efficacy. Visually, early-phase PET/CT demonstrated substantially higher specificity (66.7% vs. 16.7%), positive predictive value (87.5% vs. 73.7%), and overall accuracy (85.7% vs. 71.4%) compared to SGS, while maintaining comparable high sensitivity (93.3%). Semiquantitatively, the SUVmax of the submandibular and sublingual glands exhibited significant diagnostic utility (AUC > 0.5, P < 0.05), achieving 100% specificity and significantly outperforming volumetric parameters, which were compromised by a "background dilution effect." Clinically, early-phase global FAPI burden (TLF) correlated negatively with the systemic erythrocyte sedimentation rate (ESR). Regionally, early submandibular FTV correlated positively with the SGS excretion fraction (r = 0.594, P = 0.019), whereas the parotid glands exhibited no such correlation, corroborating the asynchronous structural progression of pSS. Furthermore, whole-body PET/CT successfully detected incidental extra-salivary fibro-inflammatory comorbidities (e.g., Hashimoto's thyroiditis, osteoarthritis).
conclusions[
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.